Bread Supplemented With Chilean Beans to Decrease Postprandial Glycoxidative Responses: A Pilot Intervention

NCT05955131 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-07-21

No results posted yet for this study

Summary

The goal of this trial is to assess in healthy subjects between 60 and 70 years the effect of glycemic and glycoxidative postprandial responses and platelet aggregation after intake of bread supplemented with Chilean beans flour when compared with a non supplemented control. The main questions to answer are:

* It is possible to decrease postprandial glycemic and glycoxidative responses by means of the intake of bread supplemented with Chilean beans flour when compared to the intake of a control bread non supplemented in healthy elderly persons?
* How is affected the platelet aggregation process during postprandial state after intake of bread supplemented with Chilean beans flour, when compared to the intake of a control bread non supplemented in healthy elderly persons?

Participants will:

* Be characterized by means of: 1) evaluation of body composition, using anthropometric techniques, bioimpedance and 2) biochemical analyses: biochemical profile, lipid profile, serum ferritin, fasting glycemia, HbA1c and insulin.
* Arrive at fast to the laboratory and eat randomly control bread, 30% Chilean beans supplemented bread or glucose. Venous blood samples will be taken from the cubital fossa of the dominant arm at: 0, 30, 60 and 120 min postprandial, only after intake of bread control and supplemented bread. In addition, capillary blood will be taken at 0, 15, 30, 60, 90 and 120 min postprandial after intake of glucose, bread control or supplemented bread.

Conditions

  • Aging

Interventions

OTHER

Nutritional acute postprandial intervention: Control bread

Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of control bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination

OTHER

Nutritional acute postprandial intervention: bread suppelmented with Chilean beans

Volunteers will arrive at fasting and blood samples (aprox. 5mL) will be obtained before (0 min) and after the intake (10 min of intake) an amount of supplemented bread containing 50g of carbohydrates, venous blood samples for determination of insulin, methyglyoxal, 3-deoxyglucosone and platelet aggregation will be collected at 30, 60, 90 and 120 mn postprandial. In addition, capillary slood will be obtained at 0, 15, 30, 60, 90 and 120 postprandial for glycemia determination.

OTHER

Nutritional acute postprandial intervention: Control glucose

Volunteers will arrive at fasting and capillary blood samples will be obtained before (0 min) and after the intake an amount of control glucose containing 50g of this monosscharide (10 min of intake), capillary slood will be also obtained at 15, 30, 60, 90 and 120 postprandial for glycemia determination.

Sponsors & Collaborators

  • Interuniversity Center for Healthy Aging

    collaborator UNKNOWN
  • Centro de Estudios en Alimentos Procesados

    collaborator OTHER
  • Clínica Fleming de Talca

    collaborator UNKNOWN
  • University of Talca

    lead OTHER

Principal Investigators

  • Felipe Ávila, PhD · School of Nutrition and Dietetics, Health Sciences Faculty, University of Talca

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2023-05-30
Completion
2024-04-30

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05955131 on ClinicalTrials.gov